Antengene’s 2023 Virtual R&D Day: Clinical Update on Key Cancer Targets (CD24, PD-L1/4-1BB, Claudin 18.2, CD73) Featuring a KOL Session on Tumor Immunotherapy
| DATE: | November 17, 2023 |
|---|---|
| TIME: | 8:30 AM EST |
| LOCATION: | Virtual |
About The Event
Dr. Anthony J. Olszanski, M.D., RPh (Fox Chase Cancer Center) will join Antengene for their 2023 R&D Day. During the event, Antengene’s Management Team will review early clinical results for four of its oncology targets:
- CD24 Monoclonal Antibody (a novel alternative “don’t eat me” target to CD47), ATG-031
- PD-L1/4-1BB Bispecific Antibody, ATG-101
- Claudin 18.2 Antibody-Drug Conjugate, ATG-022
- CD73 Oral Small Molecule Inhibitor, ATG-03
Antengene’s leadership team will provide an update on its proprietary pipeline of novel clinical and preclinical programs and future directions for 2024, with presentations from:
- Jay Mei, M.D., Ph.D. – Founder, Chairman, and CEO
- Amily Zhang, M.D. – Chief Medical Officer
- Bo Shan, Ph.D. – Chief Scientific Officer
- Godfrey Guo, M.D. – Executive Director, Clinical Development
- Bing Hou, Ph.D. – Executive Director, Drug Discovery
A live question and answer session will follow the presentation.